Virax Biolabs Group (NASDAQ:VRAX) Trading Down 4.2%

Virax Biolabs Group Limited (NASDAQ:VRAXGet Rating) traded down 4.2% on Thursday . The stock traded as low as $0.74 and last traded at $0.75. 268,711 shares were traded during trading, a decline of 85% from the average session volume of 1,768,509 shares. The stock had previously closed at $0.78.

Virax Biolabs Group Stock Performance

The firm has a 50-day moving average of $0.79 and a two-hundred day moving average of $1.51.

Hedge Funds Weigh In On Virax Biolabs Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS Group AG bought a new stake in shares of Virax Biolabs Group in the 3rd quarter valued at approximately $38,000. Legal & General Group Plc bought a new stake in Virax Biolabs Group during the 4th quarter worth approximately $73,000. Finally, Virtu Financial LLC bought a new stake in Virax Biolabs Group during the 4th quarter worth approximately $35,000. 0.46% of the stock is currently owned by institutional investors.

About Virax Biolabs Group

(Get Rating)

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products.

Read More

Receive News & Ratings for Virax Biolabs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virax Biolabs Group and related companies with's FREE daily email newsletter.